Form 4: Tourmaline Bio Director Sells Options in Novartis Merger

Tourmaline Bio director Clay B. Siegall disposed of all his employee stock options as part of the company's acquisition by Novartis AG for $48.00 per share.

Summary

• Clay B. Siegall, a Director of Tourmaline Bio, Inc. (TRML), reported the disposition of his employee stock options.
• This transaction occurred on October 28, 2025, as a result of the Agreement and Plan of Merger dated September 8, 2025.
• Novartis AG, through its subsidiary Torino Merger Sub Inc., completed a cash tender offer to acquire all outstanding shares of Tourmaline Bio for $48.00 per share.
• All outstanding and unexercised stock options were automatically canceled and converted into a cash payment.
• The cash payment for options was calculated as (Merger Consideration Exercise Price) multiplied by the number of shares underlying the option.
• Siegall disposed of 20,000 options with an exercise price of $18.55, 15,000 options at $13.91, and 16,800 options at $18.73.
• Following these transactions, Siegall beneficially owns 0 derivative securities.

Sentiment

Score: 8

Explanation: The filing reports the successful completion of a merger at a premium price, resulting in cash payouts for shareholders and option holders. This is a positive outcome for the company's investors.

Positives

• Shareholders received $48.00 in cash per share, representing a premium.
• Option holders, including Director Clay B. Siegall, received cash payouts for their in-the-money options.
• The successful completion of the merger provides certainty for investors who held Tourmaline Bio shares.

Negatives

• Tourmaline Bio, Inc. will cease to be an independent publicly traded entity.
• Director Clay B. Siegall no longer holds any derivative securities in the company.

Risks

• The filing reports a completed event, therefore it does not introduce new future risks for Tourmaline Bio as an independent entity. The primary risk of the merger not closing has been resolved.

Future Outlook

The filing reports the completion of Tourmaline Bio's acquisition by Novartis AG, indicating that Tourmaline Bio will no longer operate as an independent public entity. Its future operations and strategic direction will be integrated within Novartis AG.

Industry Context

This acquisition reflects the ongoing consolidation trend within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies like Novartis AG seek to expand their pipelines and market presence through strategic M&A activities. Such transactions often provide significant returns for shareholders of the acquired biotech firms.

Corporate Governance

Stakeholder Impact

• Shareholders received a cash payment of $48.00 per share for their common stock.
• Employee stock option holders received cash payouts for their options.
• The company's independent operations will cease, impacting employees and potentially suppliers and customers as it integrates into Novartis AG.

Next Steps

• Tourmaline Bio, Inc. will be integrated into Novartis AG.
• Tourmaline Bio's common stock will likely be delisted from public exchanges.

Key Dates

Keywords

Tourmaline Bio, TRML, Novartis AG, Merger, Acquisition, Stock Options, Insider Transaction, Form 4, Clay B. Siegall, Tender Offer